Ken Griffin Chinook Therapeutics, Inc. Transaction History

Citadel Advisors LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$18.66 - $38.58 $479,879 - $992,161	-25,717 Reduced 22.92%	86,464 $3.32 Million
Q1 2023 May 15, 2023	SELL	$21.53 - $26.8 $8.59 Million - $10.7 Million	-398,986 Reduced 78.05%	112,181 $2.6 Million
Q4 2022 Feb 14, 2023	BUY	$18.63 - $27.35 $5.41 Million - $7.94 Million	290,148 Added 131.28%	511,167 $13.4 Million
Q3 2022 Nov 14, 2022	BUY	$17.51 - $23.37 $1.83 Million - $2.45 Million	104,668 Added 89.96%	221,019 $4.35 Million
Q2 2022 Aug 15, 2022	BUY	$12.59 - $18.8 $1.12 Million - $1.67 Million	88,902 Added 323.88%	116,351 $2.04 Million
Q1 2022 May 16, 2022	BUY	$12.02 - $16.69 $180,552 - $250,700	15,021 Added 120.86%	27,449 $450,000
Q4 2021 Feb 14, 2022	SELL	$10.69 - $16.83 $1.49 Million - $2.35 Million	-139,755 Reduced 91.83%	12,428 $202,000
Q3 2021 Nov 15, 2021	SELL	$11.5 - $14.86 $1.14 Million - $1.48 Million	-99,439 Reduced 39.52%	152,183 $1.94 Million
Q2 2021 Aug 16, 2021	SELL	$13.6 - $18.98 $3.44 Million - $4.8 Million	-253,134 Reduced 50.15%	251,622 $3.55 Million
Q1 2021 May 17, 2021	SELL	$14.17 - $19.11 $595 - $802	-42 Reduced 0.01%	504,756 $7.8 Million
Q4 2020 Feb 16, 2021	BUY	$11.9 - $20.91 $6.01 Million - $10.6 Million	504,798 New	504,798 $8.01 Million

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.